SCHEMBL22324907

SCHEMBL22324907

Fc1cccc(C2CCN(c3ccn[nH]3)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
MLYCD O95822 2/20 0.46
GRM2 Q14416 2/20 0.41
SCD5 Q86SK9 3/20 0.41
KCNH2 Q12809 1/20 0.40
KCNQ2 O43526 1/20 0.40
PARP10 Q53GL7 1/20 0.39
DRD4 P21917 1/20 0.38
NPC1 O15118 1/20 0.38
ADAMTS5 Q9UNA0 1/20 0.38
BPTF Q12830 1/20 0.37
HTR1A P08908 1/20 0.37
HTR1D P28221 1/20 0.37
HTR1B P28222 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR7 P34969 1/20 0.37
HTR2B P41595 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22324936 0.84 HTR2C (0.50) KCNH2DRD4ADAMTS5HTR2C
SCHEMBL22325008 0.83 ALDH1A1 (0.44) ALDH1A1CYP3A4GRM2PARP10NPC1
SCHEMBL22324979 0.83 DHFR (0.43) CYP2D6MLYCD
SCHEMBL22324878 0.81 HTR2C (0.53) GRM2HTR1AHTR2AHTR2CHTR7
SCHEMBL22325011 0.79 HTR1A (0.37) ALDH1A1CYP3A4CYP2D6KCNH2ADAMTS5
SCHEMBL3769485 0.76 NTRK1 (0.49)
SCHEMBL22324998 0.75 GRM2 (0.44) ALDH1A1GRM2KCNH2DRD4NPC1
SCHEMBL22324803 0.75 ROCK2 (0.49) ALDH1A1CYP3A4CYP2D6MLYCDGRM2
SCHEMBL22325007 0.74 DRD2 (0.45) GRM2DRD4NPC1HTR1AHTR2A
SCHEMBL22340239 0.74 ALDH1A1 (0.44) ALDH1A1DRD4HTR1AHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479816-B2 20-HETE formation inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
US-20220144797-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-12 US disclosed
US-20220144797-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-12 US disclosed
WO-2020163689-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-08-13 WO disclosed
WO-2020163689-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144797-A1 20-HETE FORMATION INHIBITORS CYP4A22, ALOX5, ALOX15 ALDH1A1 545/4885CYP3A4 9/4885CYP2D6 97/4885
US-12479816-B2 20-HETE formation inhibitors CYP4A22, ALOX5, ALOX15 ALDH1A1 545/4885CYP3A4 9/4885CYP2D6 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.